Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake.

To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake.

To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake.

Growth hormone releasing factor (GHRF) analogs that can be used to induce endogenous growth hormone secretion are disclosed, as well as pharmaceutical compositions comprising the GHRF analogs and methods of using the GHRF analogs.

Growth hormone releasing factor (GHRF) analogs that can be used to induce endogenous growth hormone secretion are disclosed, as well as pharmaceutical compositions comprising the GHRF analogs and methods of using the GHRF analogs.

Growth hormone releasing factor (GHRF) analogs that can be used to induce endogenous growth hormone secretion are disclosed; as well as pharmaceutical compositions comprising the GHRF analogs and methods of using the GHRF analogs.

Growth hormone releasing factor (GHRF) analogs that can be used to induce endogenous growth hormone secretion are disclosed; as well as pharmaceutical compositions comprising the GHRF analogs and methods of using the GHRF analogs.

Described herein are sermorelin peptide compositions formulated for high oral bioavailability and high rates of absorption for treatment in a variety of applications, such as treatment of low testosterone, diminished endurance and energy, deficient immune system, slow metabolism, deficient cognitive function, poor sleep health, and poor bone health.

Described herein are sermorelin peptide compositions formulated for high oral bioavailability and high rates of absorption for treatment in a variety of applications, such as treatment of low testosterone, diminished endurance and energy, deficient immune system, slow metabolism, deficient cognitive function, poor sleep health, and poor bone health.